Kalaris Therapeutics Reports Q1 2025 Financials and Progress

Kalaris Therapeutics, Inc. ( (KLRS) ) has released its Q1 earnings. Here is a breakdown of the information Kalaris Therapeutics, Inc. presented to its investors.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases, with a particular emphasis on the novel anti-VEGF therapy, TH103. In its latest earnings report, Kalaris announced its financial results for the first quarter of 2025, highlighting significant developments including a merger with AlloVir and the ongoing Phase 1 trial of TH103 for neovascular Age-related Macular Degeneration (nAMD). The company reported cash and cash equivalents of $101 million as of March 31, 2025, which is expected to fund operations into the fourth quarter of 2026. This financial position was bolstered by the merger with AlloVir, which also contributed to a substantial increase in research and development expenses to $6 million, up from $2 million in the same quarter of the previous year. General and administrative expenses also rose to $4.3 million due to merger-related costs and increased operational expenses as a public company. Despite these increased costs, Kalaris ended the quarter with a net loss of $10.2 million, slightly improved from the previous year’s $3.4 million when adjusted for per-share metrics. Looking ahead, Kalaris remains optimistic about its strategic direction, particularly with the anticipated release of initial clinical data from the TH103 trial in the fourth quarter of 2025. The company is poised to continue its focus on innovative retinal therapies, supported by a strengthened financial foundation and expanded leadership team.